Price Action To Observe: Inogen Inc Stock Price Increases Today

Price Action To Observe: Inogen Inc Stock Price Increases Today

The stock of Inogen Inc (NASDAQ:INGN) is a huge mover today! About 530,188 shares traded hands or 180.58% up from the average. Inogen Inc (NASDAQ:INGN) has risen 12.42% since April 4, 2016 and is uptrending. It has outperformed by 11.33% the S&P500.
The move comes after 5 months positive chart setup for the $1.14B company. It was reported on Nov, 4 by Barchart.com. We have $70.01 PT which if reached, will make NASDAQ:INGN worth $228.00 million more.

Analysts await Inogen Inc (NASDAQ:INGN) to report earnings on November, 8. They expect $0.13 EPS, 0.00% or $0.00 from last year’s $0.13 per share. INGN’s profit will be $2.54M for 112.19 P/E if the $0.13 EPS becomes a reality. After $0.25 actual EPS reported by Inogen Inc for the previous quarter, Wall Street now forecasts -48.00% negative EPS growth.

Inogen Inc (NASDAQ:INGN) Ratings Coverage

Out of 4 analysts covering Inogen (NASDAQ:INGN), 3 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 75% are positive. Inogen has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. The stock of Inogen Inc (NASDAQ:INGN) has “Buy” rating given on Wednesday, August 12 by Leerink Swann. The stock has “Overweight” rating given by JP Morgan on Wednesday, July 13. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, August 12 report. The firm has “Strong Buy” rating by Needham given on Wednesday, November 11. On Thursday, March 24 the stock rating was initiated by Piper Jaffray with “Neutral”. Stifel Nicolaus maintained Inogen Inc (NASDAQ:INGN) on Tuesday, September 22 with “Buy” rating.

According to Zacks Investment Research, “Inogen, Inc. is a medical technology company. It offers oxygen concentrator, cart, carry bags, backpacks, external battery chargers and universal power supply for obstructive pulmonary disease patients. The Company’s products include Inogen One G3 and Inogen One G2. It sells its products in the United States and internationally. Inogen, Inc. is headquartered in Goleta, California.”

Insitutional Activity: The institutional sentiment decreased to 0.92 in Q2 2016. Its down 0.52, from 1.44 in 2016Q1. The ratio turned negative, as 22 funds sold all Inogen Inc shares owned while 54 reduced positions. 18 funds bought stakes while 52 increased positions. They now own 21.40 million shares or 1.51% more from 21.09 million shares in 2016Q1.
The California-based Rice Hall James Assoc Limited has invested 0.09% in Inogen Inc (NASDAQ:INGN). Nationwide Fund Advsr last reported 0.02% of its portfolio in the stock. Price T Rowe Assoc Md holds 239,340 shares or 0% of its portfolio. Schwab Charles Invest Mngmt last reported 0% of its portfolio in the stock. Moreover, Granahan Investment Mngmt Inc Ma has 0.61% invested in Inogen Inc (NASDAQ:INGN) for 335,241 shares. Bank Of New York Mellon Corporation has invested 0% of its portfolio in Inogen Inc (NASDAQ:INGN). Alliancebernstein Lp has 0% invested in the company for 26,450 shares. Cadence Capital Ltd owns 8,152 shares or 0.03% of their US portfolio. Morgan Stanley last reported 0% of its portfolio in the stock. Novo A S owns 3.55M shares or 18.67% of their US portfolio. Invesco Limited accumulated 284,713 shares or 0.01% of the stock. Ladenburg Thalmann Finance Services has 0% invested in the company for 100 shares. Texas Permanent School Fund holds 11,116 shares or 0.01% of its portfolio. Ridgeworth Cap Mngmt Ltd Limited Liability Company accumulated 13,513 shares or 0.01% of the stock. The Minnesota-based Arbor Cap Management Limited Liability has invested 1.42% in Inogen Inc (NASDAQ:INGN).

INGN Company Profile

Inogen, Inc., incorporated on November 27, 2001, is a medical technology company. The Firm is engaged in developing, manufacturing and marketing portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment